Prostate-specific antigen response to withdrawal of megestrol acetate in a patient with hormone-refractory prostate cancer.
Clinically significant responses after withdrawal of flutamide in patients with hormone-refractory prostate cancer (HRPC) are well documented. Failure to recognize this syndrome of response results in potential morbidity due to salvage therapy, confusion in interpretation of disease state, and introduction of a possible source of error in clinical trials. In this case report, we describe a patient with HRPC whose prostate-specific antigen levels decreased substantially in response to withdrawal of megestrol acetate. Such a response should be considered when megestrol acetate is used in the treatment of HRPC.
Wehbe
T W
TW
Department of Medical Oncology, Rhode Island Hospital, Providence, USA.
Stein
B S
BS
Akerley
W L
WL
D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D019290:Megestrol Acetate / Q000008:administration & dosage*; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000276:immunology*
D018931:Antineoplastic Agents, Hormonal; D017430:Prostate-Specific Antigen; D019290:Megestrol Acetate